Amneal Q3 revenue up 13% to $702M; GAAP net loss $0.2M, adjusted EPS $0.16; affirms guidance

Amneal Pharmaceuticals, Inc.

2024-Q3 EPS reported -$0.28 revenue$2,063,439,000

Revenue $702M (+13% YoY); adjusted EBITDA $158M (+2% YoY); adjusted diluted EPS $0.16 vs $0.19 YoY.
GAAP net loss $0.2M vs net income $10M in Q3 2023; diluted EPS $0.00.
Generics +9%, Specialty +19%, AvKARE +21%; launched CREXONT for Parkinson's disease.
Collaboration with Metsera for obesity/metabolic drugs; in-licensed high-value biosimilar.
Affirms full-year 2024 guidance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.